A5054182211- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal Tumor Research and Treatment
- Phytochemical Studies and Bioactivities
- Cancer Immunotherapy and Biomarkers
- Chromatography in Natural Products
- Helicobacter pylori-related gastroenterology studies
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Cancer therapeutics and mechanisms
- Fibroblast Growth Factor Research
- Neutropenia and Cancer Infections
- Multiple and Secondary Primary Cancers
- Cancer Research and Treatments
Hokkaido University Hospital
2016-2025
Daido University
2013-2025
Hokkaido University
2008-2022
Princeton University
2015
Tsuchiura Kyodo General Hospital
2010-2014
Saitama Cancer Center
2008-2014
Osaka National Hospital
2014
Azienda Ospedaliero-Universitaria Careggi
2014
Hokkaido Pharmaceutical University
2013
Keiyukai Sapporo Hospital
2004-2012
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent combines trifluridine and tipiracil hydrochloride, was effective the treatment of refractory colorectal cancer. We a phase 3 trial to further assess efficacy safety TAS-102 global population such patients.In this double-blind study, we randomly assigned 800 patients, 2:1 ratio, receive or placebo. The primary end point overall survival.The median survival improved from 5.3 months with placebo 7.1 hazard...
Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with poor prognosis. Futibatinib, next-generation, covalently binding FGFR1-4 inhibitor, has been shown to both antitumor activity patients FGFR-altered tumors and strong preclinical against acquired resistance mutations associated ATP-competitive FGFR inhibitors.In this multinational, open-label, single-group, phase study, we enrolled...
BackgroundNivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy first-line therapy, exploration a nivolumab-chemotherapy combination warranted. In part 1 (phase II) ATTRACTION-4, safety and nivolumab combined with S-1 plus oxaliplatin (SOX) capecitabine (CapeOX) therapy unresectable recurrent human epidermal growth factor receptor 2...
Abstract The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment patients with cancer in clinical trials has not been established. We conducted a phase 2 trial evaluate the efficacy pertuzumab plus trastuzumab for metastatic colorectal (mCRC), human epidermal growth factor receptor ( HER2 ) amplification prospectively confirmed by tissue or ctDNA analysis UMIN000027887 ). was and/or 30 mCRC. study met primary endpoint objective response rate 30% 27 tissue-positive...
For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined.To evaluate effect of panitumumab (an anti-EGFR antibody) vs bevacizumab anti-VEGF standard for treatment wild-type, left-sided, cancer.Randomized, open-label, phase 3 clinical trial at 197 sites in Japan May...
Preoperative chemoradiotherapy (CRT) and surgical resection are the standard treatment for locally advanced rectal cancer (LARC). Combining immune checkpoint inhibitors with radiation suggests a promising approach enhancing efficacy. We investigated efficacy of CRT followed by nivolumab surgery in patients LARC.In phase I, we feasibility sequentially combined CRT, 5 cycles nivolumab, radical surgery. In II, microsatellite stable (MSS) instability-high (MSI-H) LARC were evaluated.Three I...
4006 Background: BTCs have an aggressive tumor biology with limited treatment options. With a HER2-positivity rate of 5–20% in BTCs, case series and small clinical trials shown signs activity for HER2 blockade these pts. T-DXd is antibody-drug conjugate composed humanized monoclonal anti-HER2 antibody, cleavable linker, topoisomerase I inhibitor. The HERB trial investigator-initiated, multicenter, single-arm phase 2 pts HER2-expressing BTCs. Methods: Centrally confirmed (HER2-positive: IHC3+...
3501 Background: T-DXd (6.4 mg/kg, every 3 weeks [Q3W]) demonstrated antitumor activity in pts with HER2+ mCRC DESTINY-CRC01 (Siena et al. Lancet Oncol. 2021). We present primary results of DESTINY-CRC02 (NCT04744831), which assessed the efficacy and safety (5.4 6.4 mg/kg) mCRC. Methods: This was a multicenter phase 2 study. Eligible had centrally confirmed (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) Pts RAS wild-type (wt) mutant (m) were eligible. received prior...
Abstract Certain genetic alterations and right-sided primary tumor location are associated with resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer (mCRC). The phase 3 PARADIGM trial ( n = 802) demonstrated longer overall survival first-line anti-EGFR (panitumumab) versus antivascular endothelial (bevacizumab) plus modified FOLFOX6 patients RAS wild-type mCRC left-sided tumors. This prespecified exploratory biomarker analysis of 733) evaluated the...
PURPOSE Everolimus, an oral inhibitor of the mammalian target rapamycin, has shown antitumor activity in gastric cancer preclinical and phase I studies. This II study evaluated efficacy safety everolimus pretreated patients with advanced cancer. PATIENTS AND METHODS Patients who experienced progression despite prior chemotherapy received 10 mg orally daily until disease or discontinuation. The primary end point was control rate (DCR; ie, complete response, partial stable disease). Secondary...
S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP patients human epidermal growth factor receptor type 2 (HER2)-positive AGC. Patients HER2-positive AGC received S-1 (80–120 mg per day) orally on days 1–14, (60 m−2) intravenously day 1, (course 8 kg−1; course onward, 6 kg−1) 1 21-day cycle. The primary end point was response rate...
This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Irinotecan-naive (n = 82) received N-IRI (nimotuzumab 400 mg weekly 150 mg/m2 biweekly) or IRI (irinotecan until progression. The primary endpoint progression-free survival (PFS), secondary endpoints were overall (OS),...
Summary Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated efficacy and safety of Japanese non-Japanese subpopulations trial. Methods Patients were randomized 2 : 1 to 160 mg once daily or for weeks 1–3 each 4-week cycle. The primary endpoint was OS....
This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which these two drugs should be used as initial treatment.The data mCRC were treated or TFTD those drug-naive patients, between June 2014 September 2015, retrospectively collected from 24 institutions Japan. Overall survival (OS) was evaluated using...
OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating tumour DNA (ctDNA) test for detecting plasma mutational status in metastatic colorectal cancer (mCRC). We conducted multicentre, prospective study to investigate the concordance of between ctDNA and tissue DNA.mCRC patients without prior anti-EGFR antibodies or regorafenib treatment were enroled. Plasma- tissue-based determined by BEAMing, respectively.A total 280 from eight institutions eligible. The overall agreement plasma-...
LBA1 Background: PARADIGM is the first prospective trial to test superiority of PAN vs. BEV in combination with standard doublet first-line chemotherapy for patients (pts) RAS WT mCRC and left-sided primary tumors. Methods: This open-label, multicenter Japan (NCT02394795) randomly selected pts chemotherapy-naive + mFOLFOX6 or mFOLFOX6. Overall survival (OS) as endpoint was hierarchically tested tumors, followed by those full-analysis set (FAS) population. Key secondary endpoints included...